rs1135402868
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM1PM2PM4PP3PP5_Very_Strong
The ENST00000358273.9(NF1):c.5036_5041del(p.Ile1679_Tyr1680del) variant causes a inframe deletion change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. V1677V) has been classified as Likely benign.
Frequency
Genomes: not found (cov: 32)
Consequence
NF1
ENST00000358273.9 inframe_deletion
ENST00000358273.9 inframe_deletion
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 7.64
Genes affected
NF1 (HGNC:7765): (neurofibromin 1) This gene product appears to function as a negative regulator of the ras signal transduction pathway. Mutations in this gene have been linked to neurofibromatosis type 1, juvenile myelomonocytic leukemia and Watson syndrome. The mRNA for this gene is subject to RNA editing (CGA>UGA->Arg1306Term) resulting in premature translation termination. Alternatively spliced transcript variants encoding different isoforms have also been described for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 15 ACMG points.
PM1
In a hotspot region, there are 4 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 1 benign, 13 uncertain in ENST00000358273.9
PM2
Very rare variant in population databases, with high coverage;
PM4
Nonframeshift variant in NON repetitive region in ENST00000358273.9.
PP3
No computational evidence supports a deleterious effect, but strongly conserved according to phyloP
PP5
Variant 17-31326013-GTCTATA-G is Pathogenic according to our data. Variant chr17-31326013-GTCTATA-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 431651.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr17-31326013-GTCTATA-G is described in Lovd as [Pathogenic]. Variant chr17-31326013-GTCTATA-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NF1 | NM_001042492.3 | c.5036_5041del | p.Ile1679_Tyr1680del | inframe_deletion | 37/58 | ENST00000358273.9 | NP_001035957.1 | |
NF1 | NM_000267.3 | c.4973_4978del | p.Ile1658_Tyr1659del | inframe_deletion | 36/57 | NP_000258.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NF1 | ENST00000358273.9 | c.5036_5041del | p.Ile1679_Tyr1680del | inframe_deletion | 37/58 | 1 | NM_001042492.3 | ENSP00000351015 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Neurofibromatosis, type 1 Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Mar 15, 2022 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Medical Genetics, University of Parma | Feb 02, 2017 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Feb 14, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 04, 2023 | This variant, c.4973_4978del, results in the deletion of 2 amino acid(s) of the NF1 protein (p.Ile1658_Tyr1659del), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with neurofibromatosis type 1 (PMID: 10534774, 30530636; Invitae). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 431651). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | Oct 26, 2020 | - - |
not provided Pathogenic:3
Likely pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Apr 04, 2022 | The NF1 c.5036_5041delTCTATA; p.Ile1679_Tyr1680del variant (rs1135402868), also known as 4973delTCTATA for NM_000267.3, is reported in the literature in multiple individuals with NF1 (Frayling 2019, Giugliano 2019, Maani 2019, Wu 1999), and is reported in ClinVar (Variation ID: 431651). This variant is absent from the Genome Aggregation Database, indicating it is not a common polymorphism. This variant deletes an isoleucine and tyrosine residue leaving the rest of the protein in-frame. Based on available information, this variant is considered to be likely pathogenic. References: Frayling IM et al. Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation. J Med Genet. 2019 Apr;56(4):209-219. PMID: 30530636. Giugliano T et al. Clinical and Genetic Findings in Children with Neurofibromatosis Type 1, Legius Syndrome, and Other Related Neurocutaneous Disorders. Genes (Basel). 2019 Jul 31;10(8):580. PMID: 31370276. Maani N et al. NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program. Cancers (Basel). 2019 May 22;11(5):707. PMID: 31121919. Wu R et al. Germline mutations in NF1 patients with malignancies. Genes Chromosomes Cancer. 1999 Dec;26(4):376-80. PMID: 10534774. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Nov 03, 2022 | In-frame deletion of 2 amino acids in a non-repeat region; Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 31121919, 10534774, 30530636, 21089070, 31370276, 31776437) - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Aug 10, 2021 | - - |
Juvenile myelomonocytic leukemia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jul 23, 2023 | - - |
Hereditary cancer-predisposing syndrome;CN230736:Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 17, 2022 | The c.4973_4978delTCTATA pathogenic mutation (also known as p.I1658_Y1659del) is located in coding exon 36 of the NF1 gene. This pathogenic mutation results from an in-frame TCTATA deletion at nucleotide positions 4973 to 4978. This results in the in-frame deletion of isoleucine and tyrosine at amino acid positions 1658 and 1659. This variant has been determined to be the result of a de novo mutation or germline mosaicism in one individual with NF1 (Ambry internal data). This variant has also been observed in literature in multiple individuals and families with clinical diagnosis of NF1 (Wu R et al. Genes Chromosomes Cancer 1999;26(4):376-80); (Giugliano T et al. Genes (Basel), 2019 07;10:); (Maani N et al. Cancers (Basel), 2019 May;11:); (Kang E et al. J Hum Genet, 2020 Jan;65:79-89). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by in silico analysis (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). This amino acid region is well conserved in available vertebrate species. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at